EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury

Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li

Clinical and Molecular Hepatology · 01.10.2024 · 30 (4) · 585-619

DOI: 10.3350/cmh.2024.0222 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2024. Verfasst von Jia Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Liver, Oxidative Stress. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program on Modernization of Traditional Chinese Medicine, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatic ischemia‒reperfusion injury (HIRI) is a common and inevitable complication of hepatic trauma, liver resection, or liver transplantation. It contributes to postoperative organ failure or tissue rejection, eventually affecting patient prognosis and overall survival. The pathological mechanism of HIRI is highly complex and has not yet been fully elucidated. The proposed underlying mechanisms include mitochondrial damage, oxidative stress imbalance, abnormal cell death, immune cell hyperactivation, intracellular inflammatory disorders and other complex events. In addition to serious clinical limitations, available antagonistic drugs and specific treatment regimens are still lacking. Therefore, there is an urgent need to not only clarify the exact etiology of HIRI but also reveal the possible reactions and bottlenecks of existing drugs, helping to reduce morbidity and shorten hospitalizations. We analyzed the possible underlying mechanism of HIRI, discussed various outcomes among different animal models and explored neglected potential therapeutic strategies for HIRI treatment. By thoroughly reviewing and analyzing the literature on HIRI, we gained a comprehensive understanding of the current research status in related fields and identified valuable references for future clinical and scientific investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reperfusion InjuryLiverOxidative StressHumansAnimalsLiver TransplantationMolecular Targeted TherapyLiver DiseasesDisease Models, Animal

Stichwörter der Autor:innen

Animal modelHepatic ischemia-reperfusion injuryLiver diseasesPotential drug development

Autor:innen und Institutionen

  • School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program on Modernization of Traditional Chinese Medicine
  • Fundamental Research Funds for the Central Universities
  • National High-Level Talents Special Support Program

Zitieren

APA

Liu, J., Luo, R., Zhang, Y., & Li, X. (2024). Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury. Clinical and Molecular Hepatology, 30(4), 585-619. https://doi.org/10.3350/cmh.2024.0222

Vancouver

Liu J, Luo R, Zhang Y, Li X. Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury. Clinical and Molecular Hepatology. 2024;30(4):585-619. doi:10.3350/cmh.2024.0222

BibTeX
@article{Liu2024,
  author = {Liu, Jia and Luo, Ranyi and Zhang, Yinhao and Li, Xiaojiaoyang},
  title = {Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury},
  journal = {Clinical and Molecular Hepatology},
  year = {2024},
  volume = {30},
  number = {4},
  pages = {585--619},
  doi = {10.3350/cmh.2024.0222}
}
Kostenlos starten →